

Emergency and Critical Pathology Group

Publications: 21
Q1: 10

RESEARCH ACTIVITY

Publications

- Abdukahil SA, Abe R, Abel L, Absil L, Acker A, Adachi S, Adam E, Adriaio D, Ainscough K, Hs-sain AA, Zucman D. (et al). COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study. *Infection*. 2021; 49(5): 889-

905. Article. IF: 7.455; Q1


- Avendaño-Ortiz J, Lozano-Rodríguez R, Martín-Quirós A, Maroun-Eid C, Terron-Arcos V, Montalbán-Hernández K, Valentin J, del Val EM, García-Garrido MA, del Balzo-Castillo A, Casalvilla-Duenas JC, Peinado M, Gómez L, Herrero-Benito C, Rubio C, Cubillos-Zapata C, Pascual-Iglesias A, del Fresno C, Aguirre LA, López-Collazo E. SARS-CoV-2 proteins induce

endotoxin tolerance hallmarks: a demonstration in patients with COVID-19. *J Immunol*. 2021; 207(1): 162-74. Article. IF: 5.426; Q2

- Avendaño-Ortiz J, Lozano-Rodríguez R, Martín-Quirós A, Terron V, Maroun-Eid C, Montalbán-Hernández K, Valentin-Quiroga J, García-Garrido MA, del Val EM, del Balzo-Castillo A, Peinado M, Gómez L, Herrero-Benito C, Rubio C, Casalvilla-Duenas JC, Gómez-Campelo P,

Pascual-Iglesias A, del Fresno C, Aguirre LA, López-Collazo E. The immune checkpoints storm in COVID-19: Role as severity markers at emergency department admission. *Clin Transl Med*. 2021; 11(10): e573. Letter. IF: 8.554; Q1

- Berenguer J, Borobia AM, Ryan P, Rodríguez-Baño J, Bellón JM, Jarrin I, Carratala J, Pachon J, Carcas AJ, Yllescas M, Arribas JR. Development and validation of a prediction model for 30-day



- mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. *Thorax*. 2021; 76(9): 920-9. Article. IF: 9.102; Q1
- Chen YT, Fuertes PR, Saez PO, Villegas TV, Soto AB, Calle PF, Cardona CC, Mora JC, Canadas MJ, Tong HY, Borobia AM. Efficacy of a fast-track pathway for managing uncomplicated renal or ureteral colic in a hospital emergency department: the STONE randomized clinical trial of Sonography and Testing of a Nephrolithiasis Episode. *Emergencias*. 2021; 33(1): 23-8. Article. IF: 5.345; Q1
 - Cogliati C, Bosch F, Tung-Chen Y, Smallwood N, Torres-Macho J. NNLung ultrasound in COVID-19: Insights from the frontline and research experiences. *Eur J Intern Med*. 2021; 90: 19-24. Article. IF: 7.749; Q1
 - COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. *Nature*. 2021; 600(7889): 472-7. Article. IF: 69.504; D1
 - Dopico LR, Tung-Chen Y, Barco MP, García AM. Monitoring of the rehabilitation therapy of COVID-19 effort dyspnea. *Enferm Infecc Microbiol Clin*. 2021; 39(5): 258-9. Letter. IF: 1.994; Q4
 - Gómez-Junyent J, Lora-Tamayo J, Baraia-Etxaburu J, Sánchez-Somolinos M, Iribarren JA, Rodríguez-Pardo D, Praena-Segovia J, Sorli L, Bahamonde A, Riera M, Rico A, del Toro MD, Morata L, Cobo J, Falgueras L, Benito N, Munez E, Jover-Saenz A, Pigrau C, Ariza J, Murillo O. Implant removal in the management of prosthetic joint infection by staphylococcus aureus: outcome and predictors of failure in a large retrospective multicenter study. *Antibiotics (Basel)*. 2021; 10(2): 118. Article. IF: 5.222; Q1
 - Gutiérrez-Gutiérrez B, del Toro MD, Borobia AM, Carcas A, Jarrín I, Yllescas M, Ryan P, Pachón J, Carratala J, Berenguer J, Arribas JR, Rodríguez-Bano J. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. *Lancet Infect Dis*. 2021; 21(6): 783-92. Article. IF: 71.421; D1
 - Hernández-Piriz A, Tung-Chen Y, Jiménez-Virumbrales D, Ayala-Larranaga I, Barba-Martín R, Canora-Lebrato J, Zapatero-Gaviria A, De Casasa-Sánchez GG. Importance of lung ultrasound follow-up in patients who had recovered from coronavirus disease 2019: Results from a prospective study. *J Clin Med*. 2021; 10(14): 3196. Article. IF: 4.964; Q2
 - Martín-Quirós A, Maroun-Eid C, Avendaño-Ortiz

- J, Lozano-Rodríguez R, Valentín Quiroga J, Terrón V, Montalbán-Hernández K, García-Garrido MA, Muñoz del Val E, del Balzo-Castillo A, Rubio C, Cubillos-Zapata C, Aguirre LA, López-Collazo E. Potential role of the galectin-9/tim-3 axis in the disparate progression of sars-cov-2 in a married couple: a case report. *Biomed Hub*. 2021; 6(1): 48-58-. Article. Not Indexed
- May L, Quirós AM, Ten Oever J, Hoogerwerf J, Schoffelen T, Schouten J. Antimicrobial stewardship in the emergency department: characteristics and evidence for effectiveness of interventions. *Clin Microbiol Infecc*. 2021; 27(2): 204-9. Review. IF: 13.31; D1
- Schoffelen T, Schouten J, Hoogerwerf J, Quirós AM, May L, Ten Oever J, Hulscher M. Quality indicators for appropriate antimicrobial therapy in the emergency department: a pragmatic Delphi procedure. *Clin Microbiol Infecc*. 2021; 27(2): 210-4. Article. IF: 13.31; D1
- Tong HY, Borobia AM, Quintana-Díaz M, Fabra S, González-Vinolis M, Fernández-Capitan C, Rodríguez-Dávila MA, Lorenzo A, López-Parra AM, Ruiz-Giménez N, Abad-Santos F, Suárez C, Madridano O, Gómez-Cerezo JF, Llamas P, Baeza-Richer C, Arroyo-Pardo E, Carcas AJ. Ace-nocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolism: a randomised clinical trial. *J Clin Med*. 2021; 10(13): 2949. Article. IF: 4.964; Q2
- Torres-Macho J, Sánchez-Fernández M, Arnanz-González I, Tung-Chen Y, Franco-Moreno AI, Duffort-Falco M, Beltran-Romero L, Rodríguez-Suárez S, Bernabeu-Wittel M, Urbano E, Méndez-Bailon M, Roque-Rojas F, García-Guijarro E, García-Casasola G. Prediction accuracy of serial lung ultrasound in covid-19 hospitalized patients (Pred-Echovid Study). *J Clin Med*. 2021; 10(21): 4818. Article. IF: 4.964; Q2
- Tung-Chen Y, Algora-Martín A, Rodríguez-Roca S, de Santiago AD. COVID-19 multisystemic inflammatory syndrome in adults: a not to be missed diagnosis. *BMJ Case Rep*. 2021; 14(4): e241696. Article. Not Indexed
- Tung-Chen Y, Alonso-González B, Arroyo-Rico I. Lung ultrasonography unmasking the asymptomatic SARS-CoV-2 carrier. *Med Clin-Barcelona*. 2021; 156(4): 196-7. Letter. IF: 3.2; Q2
- Tung-Chen Y, González-Vinolis M, Santos-Olmo RMT. Tele-ultrasound guided through WhatsApp. *Med Clin-Barcelona*. 2021; 157(11): E343-4. Letter. IF: 3.2; Q2
- Tung-Chen YL, Algora-Martín A, Llamas-Fuen-

- tes R, Rodríguez-Fuertes P, Virto AMM, Sanz-Rodríguez E, Alonso-Martínez B, Núñez MAR. Point-of-care ultrasonography in the initial characterization of patients with COVID-19. *Med Clin-Barcelona*. 2021; 156(10): 477-44. Article. IF: 3.2; Q2
- Tung-Chen YL, Marin-Baselga R, Soriano-Arroyo R, Munoz-del Val E. Time course of lung changes on thoracic ultrasound of mild COVID-19 patients. *Enferm Infecc Microbiol Clin*. 2021; 39(1): 46-8. Letter. IF: 1.994; Q4

■ Research projects

Martín Quirós A. Impacto del retraso en el inicio de la antibioterapia e identificación de biomarcadores pronósticos en la evolución de pacientes con sepsis a shock séptico (PI20/01589). ISCI. 2021-2023.

Management centre: FIBHULP

Martín Quirós A. Development of robust and innovative vaccine effectiveness (DRI-VE). EU. 2020-2021.

Management centre: FIBHULP

■ Clinical trials

López Ortego, P. Retrospective cohort safety study of captopril administered for prevention or treatment of heart failure in paediatric patients from birth to 1 year of age.

Type: Estudios, fase EPA-OD.

HULP code: Appendix 1 PI-3351.

Sponsored by: Proveca Ltd.

Signed date: 27/04/2021

Martín Quirós, A. Estudio clínico de fase 2/3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la farmacocinética de mk-4482 en adultos no hospitalizados con COVID-19.

Type: Clinical Trials, phase II.

HULP code: Appendix 1 5693.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 16/03/2021

Martín Quirós, A. Estudio de fase II, aleatorizado, doble ciego y controlado con placebo para evaluar la actividad antiviral, la seguridad, la farmacocinética y la eficacia de ro7496998 (at-527) en pacientes adultos no hospitalizados con COVID-19 leve o moderada.

Type: Clinical Trials, phase II.

HULP code: 5836 WV43042.

Sponsored by: F.Hoffmann-La Roche Ltd.

Signed date: 09/04/2021

Martín Quirós, A. Estudio clínico de fase 2/3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la farmacocinética de mk-4482 en adultos no hospitalizados con COVID-19.

Type: Clinical Trials, phase II.

HULP code: Appendix 2 5693.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 14/07/2021


Martín Quirós, A. Estudio intervencional de fase II/III, doble ciego, de dos grupos para evaluar la eficacia y la seguridad de pf-07321332/ritonavir administrados oralmente y comparado con placebo en pacientes adultos sintomáticos no hospitalizados con COVID-19 que tengan riesgo bajo de progresar a enfermedad severa.

Type: Clinical Trials, phase III.

HULP code: 5953 C4671002.

Sponsored by: Pfizer, S.L.U.

Signed date: 04/08/2021



Martín Quirós, A. Estudio intervencional de fase II/III, doble ciego, de dos grupos para evaluar la eficacia y la seguridad de pf-07321332/ritonavir administrados oralmente y comparado con placebo en pacientes adultos sintomáticos no hospitalizados con COVID-19 que tengan riesgo elevado de progresar a enfermedad severa.

Type: Clinical Trials, phase III.

HULP code: 5955 C4671005.

Sponsored by: Pfizer, S.L.U.

Signed date: 04/08/2021

Martín Quirós, A. Estudio de fase II/III, aleatorizado, doble ciego, con doble simulación y controlado con placebo para evaluar la seguridad y eficacia de 2 pautas de pf-07321332/ritonavir administrados oralmente para prevenir los síntomas de la infección por SARS-CoV-2

en adultos que hayan tenido contacto doméstico con personas infectadas por SARS-CoV-2.

Type: Clinical Trials, phase III.

HULP code: 5954 C4671006.

Sponsored by: Pfizer, S.L.U.

Signed date: 14/09/2021

Martín Quirós, A. Estudio de fase 3, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de mk-4482 en la prevención de la COVID-19 (infección por sarscov-2, confirmada por el laboratorio, con síntomas) en adultos que conviven con una persona con COVID-19.

Type: Clinical Trials, phase III.

HULP code: 5929 MK-4482-013.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 24/08/2021